The pharmacological characteristics of azole are diverse. Only a few medications can reduce the risk of clot formation, and they all have serious side effects. At present time there has to be more focus on to cure this type of complication beacause due to environmental, emotional, physical, other biological incidents are much related to this condition. Resistance has developed to existing medications, prompting the implementation of novel medications with a greater activity profile. The synthesis of a 1,3,4-oxadiazole derivative from nicotinic acid as well as its antithrombotic activity is described in this paper.
Cite this article:
Vishal T. Khot, S. K. Mohite, C. S. Magdum. Synthesis of novel 1,3,4-oxadiazole derivatives of nicotinic acid and its in-vitro antithrombotic activity. Asian Journal of Research in Chemistry. 2021; 14(6):431-4. doi: 10.52711/0974-4150.2021.00074
Vishal T. Khot, S. K. Mohite, C. S. Magdum. Synthesis of novel 1,3,4-oxadiazole derivatives of nicotinic acid and its in-vitro antithrombotic activity. Asian Journal of Research in Chemistry. 2021; 14(6):431-4. doi: 10.52711/0974-4150.2021.00074 Available on: https://ajrconline.org/AbstractView.aspx?PID=2021-14-6-7
1. Batool, Majda, et al. Molecular Docking, Computational, and Antithrombotic Studies of Novel 1, 3, 4-Oxadiazole Derivatives. International Journal of Molecular Sciences. 2018; 19(11): 3606.
2. Bethge, Katrin, Heinz H. Pertz, and Klaus Rehse. New oxadiazole derivatives showing partly antiplatelet, antithrombotic and serotonin antagonistic properties. Archiv der Pharmazie: An International Journal Pharmaceutical and Medicinal Chemistry. 2005; 338. 2‐3: 78-86.
3. Vishwanathan, B., B. M. Gurupadayya, and K. Venkatan Sairam. In silico and antithrombotic studies of 1, 3, 4-oxadiazoles derived from benzimidazole. Bangladesh Journal of Pharmacology. 2016. 11.1: 67-74.
4. Yildiz, Ali Kemal, et al. New antithrombotics with an indazole structure. Archiv der Pharmazie: An International Journal Pharmaceutical and Medicinal Chemistry. 2004; 337.6: 311-316.
5. Amin, Kamelia M., et al. New series of 6-substituted coumarin derivatives as effective factor Xa inhibitors: Synthesis, in vivo antithrombotic evaluation and molecular docking. Bioorganic Chemistry. 2014; 52: 31-43.
6. Basra, M. A., et al. Anti-inflammatory, antithrombotic and molecular docking studies of 1, 3, 4 Oxadiazole derivatives in rats. J Biomed Sci. 2019; 8.2: 4.
7. Tao, Jing, et al. Synthesis of 1, 3, 4‐Oxadiazoles and 1, 3‐Thiazolidinones Containing 1, 4, 5, 6‐Tetrahydro‐6‐ pyridazinone. Journal of the Chinese Chemical Society. 2006; 53.5: 1193-1197.
8. Sekhar, M. Madhu, et al. Synthesis and antimicrobial activity of pyrimidinyl 1, 3, 4-oxadiazoles, 1, 3, 4-thiadiazoles and 1, 2, 4-triazoles. European Journal of Medicinal Chemistry. 2018; 145: 1-10.
9. El‐Sayed, Wael A., et al. Synthesis and antimicrobial activity of new C‐furyl glycosides bearing substituted 1, 3, 4‐oxadiazoles." Journal of Heterocyclic Chemistry. 2011; 48.5: 1006-1013.
10. Deeba, Farah, et al. Synthesis, characterization and biological activities of 1, 3, 4-oxadiazole derivatives of nalidixic acid and their copper complexes. Chemistry International. 2018; 4.4: 206-215.
11. Nayak, Soukhyarani Gopal, and Boja Poojary. A Review on the Preparation of 1, 3, 4-Oxadiazoles From the Dehydration of Hydrazines and Study of Their Biological Roles. Chemistry Africa. 2019; 2.4 : 551-571.
12. Ramzan, Ayesha, et al. Synthesis and Antiplatelet Potential Evaluation of 1, 3, 4-Oxadiazoles Derivatives. Zeitschriftfür Physikalische Chemie. 2019; 233.12: 1741-1759.
13. Bharadwaj, S. Shashidhar, et al. Efficient synthesis and in silico studies of the benzimidazole hybrid scaffold with the quinolinyloxadiazole skeleton with potential α-glucosidase inhibitory, anticoagulant, and antiplatelet activities for type-II diabetes mellitus management and treating thrombotic disorders. ACS omega 3. 2018; 10 : 12562-12574.
14. El Sadek, Mohamed M., et al. Synthesis and bioassay of a new class of furanyl-1, 3, 4-oxadiazole derivatives. Molecules. 2013; 18.7: 8550-8562.